CellTrust Receives Ex Parte Reexamination Certificates from the U.S. Patent and Trademark Office which rejects challenges to Original CellTrust Patent Claims and confirms the Patentability of New CellTrust Patent Claims

CellTrust today announced that the company was victorious in the third-party challenge in front of the U.S. Patent and Trademark Office (“the USPTO”) for claims of U.S. Patent No. 9,775,012 (“the ’012 Patent”) and claims of U.S. Patent No. 10,778,837 (“the ’837 Patent”) and has received Ex Parte Reexamination Certificates from the USPTO.

The USPTO rejected the third-party’s challenge to the original patent claims, which remain the subject of other ongoing litigation. Even more, the USPTO confirmed the patentability of new patent claims that are not currently the subject matter of ongoing litigation.

“The USPTO’s issuance of the Ex Parte Reexamination Certificates confirms CellTrust’s continuing efforts to protect its investments in innovation,” said Sean Moshir, CellTrust Chairman and CEO.

The Ex Parte Reexamination Certificates and USPTO opinion can be publicly viewed at the USPTO Patent Center website: https://patentcenter.uspto.gov

About CellTrust Corporation

CellTrust Corporation is a mobile security and communications compliance leader for financial services, government, and other highly regulated sectors. CellTrust’s mobile communication platform and flagship SL2™ Enterprise Capture streamline mobile communication compliance through SMS/text, chat and voice capture, moderation, gateway hold, retention, and eDiscovery. CellTrust helps organizations meet regulatory recordkeeping requirements, such as SEC, CFTC, FINRA, SOX, FCA, MiFID II, FOIA, Sunshine Laws, Public Records Laws, and HIPAA. CellTrust is a member of the Microsoft Intelligent Security Association. www.celltrust.com

©2024 CellTrust Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104649005/en/